Cell-free DNA analysis for the determination of fetal red blood cell antigen genotype in alloimmunized pregnancies - Rego, Shannon; Balogun, Olaide ASHIMI; Emanuel, Kirsten; Overcash, Rachael; Gonzalez, Juan M.; Denomme, Gregory A.; Hoskovec, Jennifer; King, Haley; Wilson, Ashley; Wynn, Julia; Moise, Kenneth J. (medRxiv, 2024)
Objective The objective of the study is to evaluate the accuracy of NGS based quantitative cfDNA analysis for fetal antigen genotyping in alloimmunized pregnancies undergoing clinical testing in practices across the US as early as ten weeks gestational age. Timely identification of the fetal red blood cell antigen genotype for the antigen to which the pregnant person is alloimmunized is vital for determining risk for hemolytic disease of the fetus or newborn (HDFN) and guiding management. The currently recommended approach to assessing risk for HDFN in the US relies on determining the antigen status of the reproductive partner and/or amniocentesis–an approach with limitations such as low uptake and the potential for nonpaternity, which could be alleviated by the utilization of cfDNA testing to determine fetal antigen status.Methods Patients with alloimmunized pregnancies undergoing clinical fetal antigen cfDNA analysis were recruited to the study along with the neonates resulting from the pregnancies via outreach from the laboratory. The laboratory issued the results prospectively as a part of clinical care. After delivery, neonatal buccal swabs were sent to an outside, independent laboratory for antigen genotyping. The outside laboratory was blinded to the fetal cfDNA results, and the results were compared. Concordance was reported for the fetal antigen cfDNA analysis for antigens to which the pregnant person was alloimmunized as well as for all antigens for which the pregnant person was genotype negative.Results A total of 156 participants from 120 clinics who received clinically ordered cfDNA fetal antigen testing provided neonatal buccal swabs for genotyping following delivery. Concordance between cfDNA analysis results and neonatal genotype was determined for 465 antigen calls for the following antigens K1 (n=143), E (124), C (60), Fya (50), c (47), and D(RhD) (41). These 465 calls included 145 where the fetus was antigen positive and 320 where the fetus was antigen negative. We observed complete concordance between prenatal fetal antigen cfDNA analysis results and neonatal genotypes for the 465 calls, resulting in 100% sensitivity, specificity, and accuracy across a racially and ethnically diverse cohort.Conclusion This study demonstrates that cfDNA analysis for determining fetal antigen genotype is more accurate than real life application of the current recommendations, i.e., partner testing and amniocentesis, in a diverse US population. In addition, this noninvasive approach reduces barriers to obtaining timely and accurate information about fetal antigen genotype. Taken together with previously published evidence, this study supports the implementation of cfDNA testing to manage alloimmunized pregnancies as a clinically useful and cost effective approach.Competing Interest StatementJ.H., and J.W. are employees of BillionToOne, Inc. and have options/equity in BillionToOne, Inc. H.K. and A.W. are paid contractors with BillionToOne, Inc. K.J.M. is a paid consultant of BillionToOne, Inc. S.R. was an employee of BillionToOne, Inc. O.A.A., K.E., and R.O. received research funding from BillionToOne, Inc. J.M.G and G.A.D. have no conflicts of interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG - IRB a private IRB gave ethical approval for this work. WCG IRB protocol number 20225380I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAn anonymized data set is available by request